CardioVascular Safety – What are the Key Issues Regarding Blood Pressure Assessment During Clinical Development
Nov 7 2013 11:00AM - Nov 7 2013 12:30PM | Online
This webinar will be broadcast in Eastern Time (ET)
This webinar will focus on recent safety considerations regarding blood pressure increases during drug development, how blood pressure should ideally be assessed during development, regulatory considerations, technical aspects, and case examples. There will be ample time for the panel to address questions.
This webinar was developed in collaboration with the Cardiac Safety Research Consortium (CSRC)
Who Should Attend
Physicians, pharmacists, nurses, regulatory experts and others involved in:
- Development of pharmaceutical products
- Drug Development
- Risk Management
At the conclusion of this webinar, participants should be able to:
- Explain the current safety issues surrounding drug-induced BP elevations
- Discuss how BP is best assessed during clinical development
- Describe the ideal technical approaches to assessing BP changes during development
Register for all three webinars in the Cardiovascular Safety Series and save 15%*
for minimum system requirements.
Drug Information Association has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102.
As an IACET Authorized Provider, Drug Information Association offers CEUs for its programs that qualify under the ANSI/IACET Standard. Drug Information Association is authorized by IACET to offer .2 CEUs for this program. Participants must attend the entire program in order to be able to receive an IACET statement of credit. No partial credit will be awarded.
DIA’s Certificate Program Statement
This program is part of DIA’s Certificate Program and is awarded the following:
• Clinical Safety and Pharmacovigilance Certificate Program: 1 Elective Units
• Regulatory Affairs Certificate Program: 1 Elective Units
For more information go to www.diahome.org/certificateprograms
|CardioVascular Safety – Blood Pressure
It is DIA policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Disclosure statements will be included in the course materials.
Statement of Credit:
If you would like to receive a statement of credit, you must participate in the live webinar, and complete the online credit request process through My Transcript. To access My Transcript, please go to www.diahome.org, select “Login to My DIA” and you will be prompted for your user ID and password. Select “My Transcript” (left side bar) and “Credit Request” to process your credit request. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on Thursday, November 21, 2013.
- Government (Full Time) Individual
- Charitable Nonprofit/Academia Individual
- Group Site
- Group Plus
- Member Industry Individual
- NonMember Industry Individual
*Register for all three webinars in the Cardiovascular Safety Series and save 15%. Offer expires October 31, 2013. Follow the links below for information on the rest of the series.
CardioVascular Safety: The New Paradigm – Proarrhythmic Assessment of New Drugs Without the Thorough QT Study
December 3 and 10
Evaluation and Management of Cardiac Conditions in Oncology Patients
Part 1 – Updates in Cardio-Oncology - December 3
Part 2 – Treatments – December 10
- Group site registration is a license for ONE internet login allowing multiple viewers from one location.
- Group Plus is a license for up to FIVE internet logins allowing one or more viewers at each login location.
No refunds will be provided in the event of a participant’s cancellation since all costs for this webinar have been prepaid by DIA. DIA reserves the right to modify or cancel programs and/or substitute presenters or panelists. DIA is not responsible for failure to deliver programs due to circumstances beyond its control.
Participants with Disabilities: Reasonable accommodations will be made available to persons with disabilities who attend an educational activity. Contact the DIA office in writing at least 15 days prior to event to indicate your needs.
Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the Drug Information Association. Speakers, agenda and CE information are subject to change without notice. Recording of any DIA educational material in any type of media is prohibited without prior written consent from DIA.